Company profile: 3F Therapeutics
1.1 - Company Overview
Company description
- Provider of cardiovascular devices and invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system, to reduce surgical cross-clamp and cardio-pulmonary bypass time, with utilization for congestive heart failure.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 3F Therapeutics
Foldax
HQ: United States
Website
- Description: Provider of synthetic heart valve solutions delivering non-thrombogenic aortic and mitral valves at lower cost, including TRIA surgical and TAVR valves with computer-designed frames and leaflets to match natural function; LifePolymer non-animal polymer offering biostability, biocompatibility and resistance to calcification; automated robotic manufacturing, FEA design, and polymer applications in medical and industrial devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foldax company profile →
GB Sciences
HQ: United States
Website
- Description: Provider of research and biotechnical development focused on plant-based therapeutics, including the PhAROS AI drug discovery platform to identify and predict active ingredients; therapies for Parkinson’s disease (animal proof-of-concept, US patent); COVID-related cytokine release syndrome therapies (positive proof-of-concept); and oral nanoparticle pain therapeutics (US patent, ongoing animal studies).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GB Sciences company profile →
Milestone Pharmaceuticals
HQ: Canada
Website
- Description: Provider of small-molecule therapeutics for cardiovascular diseases, including Etripamil, a nasal spray calcium channel blocker in development for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), and OutsmartPSVT.com, a website to help patients and caregivers manage PSVT with their healthcare team.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Milestone Pharmaceuticals company profile →
Relypsa
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of non-absorbed polymeric drugs for cardiovascular and renal diseases, specializing in iron deficiency, nephrology, and cardio-renal therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Relypsa company profile →
Semprus Biosciences
HQ: United States
Website
- Description: Provider of medical devices implementing the multi-faceted Semprus technology, currently focused on developing a vascular access catheter incorporating a single surface modification. Headquartered in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semprus Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 3F Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 3F Therapeutics
2.2 - Growth funds investing in similar companies to 3F Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 3F Therapeutics
4.2 - Public trading comparable groups for 3F Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →